Wechselwirkungen · Ibrance
IBRANCE 75 mg film-coated tablets IBRANCE 100 mg film-coated tablets IBRANCE 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 32
HOS-132511 · Präparat HOS-097230
Based on in vitro data, palbociclib is predicted to inhibit intestinal P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) mediated transport. Therefore, administration of palbociclib with medicinal products that are substrates of P-gp (e.g., digoxin, dabigatran, colchicine) or BCRP (e.g., pravastatin, rosuvastatin, fluvastatin, sulfasalazine) may increase their therapeutic effect and adverse reactions. Based on in vitro data, palbociclib may inhibit the uptake transporter organic cationic transporter OCT1 and then may increase the exposure of medical product substrates of this transporter (e.g., metformin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfasalazine (HOS-089673) rosuvastatin (HOS-086307) digoxin (HOS-086172) dabigatran (HOS-112096) fluvastatin (HOS-086305) colchicine (HOS-086147) metformin (HOS-091032) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T16:43:00Z · SHA-256 73a98bcaed2e5b347266ff9f037099270b545348fdf729a2479eedc3e06fd319 · Passage edd9eba7a0c0c471b554ae39ea645ae60042cbb1cdeb1db12005e9643996c4c7 · Zeichen 3978–4607 im Abschnitt